Typhim Vi®: Clinical Trials

6 trials of Typhim Vi®, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 3 Phase 1, 1 Early Phase 1, 1 Not applicable, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3
Early Phase 11Completed 1
Not applicable1Completed 1
Phase 21Completed 1

Follow Typhim Vi®: new trials by email Literature Review of Typhim Vi® trials Research Report on Typhim Vi®

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults
EuTCV, Typbar-TCV™, Typhim Vi® - Typhoid Fever
Phase 1CompletedEuBiologics Co.,Ltd752019-03-162019-12-09
Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine
Vi-DT, Typhim Vi®, VAXIGRIP® - Typhoid
Phase 1CompletedInternational Vaccine Institute1442016-05-192020-04-28
Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation
Typhoid vaccine, Concentrate beetroot Juice, Concentrate beetroot Juice (Placebo) - Cardiovascular Diseases
Phase 1CompletedQueen Mary University of London782016-04-012022-07-20
Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers
Typhoid Vaccine, Placebo - Typhoid Vaccine on Sleep
Not applicableCompletedUniversity of Oxford162015-02-012018-05-14
Investigation of the Influence of Gender on Cardiovascular Function
Typhoid vaccine, Cantharidin - Cardiovascular Function
Early Phase 1CompletedQueen Mary University of London562012-03-012017-06-14
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
CYD dengue vaccine serotypes (1, 2, 3, 4)., Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide - Dengue Virus, Dengue Fever
Phase 2CompletedSanofi Pasteur, a Sanofi Company1802009-03-012022-04-05

Conditions studied

Typhoid Fever (2)  ·  Cardiovascular Diseases (1)  ·  Dengue (1)  ·  Depression (1)  ·  Inflammation (1)  ·  Severe Dengue (1)

Sponsors

Queen Mary University of London (2)  ·  EuBiologics Co.,Ltd (1)  ·  International Vaccine Institute (1)  ·  Sanofi Pasteur, a Sanofi Company (1)  ·  University of Oxford (1)

Countries

United Kingdom (2)  ·  Philippines (1)  ·  Vietnam (1)

Top investigators

Amrita Ahluwalia, BSC PhD (1)  ·  Amrita Ahluwalia, BSc PhD (1)  ·  Ann L Sharpley, BSc, PhD (1)  ·  Maria Rosario Capeding, MD (1)

Results publications

PMID 27503474, PMID 27893465, PMID 29776750, PMID 33849723, PMID 40209616

NIH funding

2014 (1)